🇪🇺EU promotes Endolysin Technology, Set to Replace Antibiotics: Micreos Awarded €2.5 Million for Breakthrough for Skin Problems Including Acne and Eczema wallstreet-online.de/nachricht/1189… #AMR #AntibioticResistance #eczema

New report: Every 15 minutes, someone in the US dies of a drug-resistant superbug. No time to lose, no need to wait! #AMR #AntibioticResistance #superbugs #endolysins

🎊🍾Gladskin Launches in USA - Micreos Scaling up finanznachrichten.de/nachrichten-20… #endolysins #AMR #Staphefekt #AntibioticResistance #dermatology #neurodermitis #eczema

We‘re hiring! ✅Want to join a fast-growing company? ✅Want to be part of a young, enthusiastic team? ✅ Want to help to develop the world's first targeted antibacterial products, set to replace antibiotics? Apply! #HiringNow #phages #phagetechnology bcfcareer.nl/vacancies/vaca…

Read about our technology here: Jumbovirussen zijn vijanden van bacteriën – en meer nrc.nl/nieuws/2020/02… #AMR #phages #endolysin #innovation

#AMR contributes to the risk of novel deadly microbes spreading into human populations. And we experience on a daily basis, what happens, when treatment options lack. All this forces us to break with the old and imagine our world anew. We are ready vimeo.com/405387932

Important read about how superbugs will complicate the care of many #COVID19 patients. statnews.com/2020/03/23/ant… #amr #endolysins #AntibioticResistance

Research is continuing to provide evidence that our technology will change the way inflammatory skin conditions, like #eczema, are treated. Promising news for the milllions of people who are affected by these skin conditions world wide. manchester.ac.uk/discover/news/…

We’re excited to share that we’ve raised another €32 million to continue our research into endolysin-based alternatives to antibiotics. This will allow us to further our research into solutions for #atopicDermatitis,#sepsis, diabetic wounds and cancer. prnewswire.co.uk/news-releases/…

We‘re happy to announce that Matt Regan has joined Micreos to run our new Pharmaceutical business! Welcome on board Matt! prnewswire.co.uk/news-releases/…

Interesting interview with microbiologist Bjorn Herpers on Dutch #BNR News Radio! Learn more about MICREOS's Endolysin Technology / Staphefekt™ and Gladskin #eczema study results. #endolysins #MRSA bnr.nl/player/audio/1…

We are delighted to announce two new additions to the Micreos Pharmaceuticals Team: Trine Ahlgreen + Carsten Edwards. These key hires at the executive level will help us in our continued fight against Anti-Microbial Resistance (#AMR)! businesswire.com/news/home/2022…

Fresh from the paper mill - excited to present our new paper on the incredible activity of linker-modified endolysins against #Staphylococcus on skin - many thanks to #FritzEichenseher, #MathiasSchmelcher, many other co-authors, and support from Micreos ! doi.org/10.1128/aac.02…

“How we respond as a #pharmaceutical industry to this global crisis of #antimicrobialresistance is critical,” says Micreos Pharmaceuticals CEO Matt Regan. Learn how Micreos is innovating beyond #antibiotics with novel technology bit.ly/3aHcaMf #AMR